Rigor Reviewed

Rigor-Reviewed Manuscript

Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.

Name: Αlpha¹ Rigor Record — Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.
Item: Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.
Rating: 84
Author: Αlpha¹

Lentz RJ, Frederick-Dyer K, Planz VB, Koyama T, Aboudara MC, Avasarala SK, Casey JD, Cheng GZ, D'Haese PF, Duke JD, Grogan EL, Hoopman TC, Johnson J, Katsis JM, Kurman JS, Low SW, Mahmood K, Rickman OB, Roller L, Salmon C, Shojaee S, Swanner B, Wahidi MM, Walston C, Silvestri GA, Yarmus L, Rahman NM, Maldonado F, Interventional Pulmonary Outcomes Group

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1.25★ (Critical), 0 critical, 8 high issues for “Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1.25 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×5−2.5★
ReportingData & code availability not met−0.5★
CitationsUnresolved reference ×2−0.5★
ReportingEthical approvals partially met−0.25★

Model-reported confidence: highReviewer agreement: moderateEngine: 7.29.0Source: full text

Problems surfaced7 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Methods and results do not matchAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Ethics/consent reporting incompleteAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The VERITAS trial is a well-designed multicenter randomized noninferiority trial with clear methods and transparent reporting. Its main weaknesses are the absence of a data availability statement, minor imprecision in p-value reporting, and a critical internal discrepancy in the abstract safety percentages that requires correction.

All eight dimensions were applicable. The reviewers diverged on key resources (warn vs pass) and statistical analysis (pass vs warn); the synthesized statuses reflect the majority or more evidence-based judgment. The statistics verification component checked only 3 tests (all consistent); coverage is limited and does not constitute a comprehensive audit.

7 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

5 integrity concerns flagged (2 high).

Reporting

Eight Dimensions6 pass · 1 warn · 1 fail

Prior work is cited (references 1-20) highlighting the trade-offs between transthoracic biopsy (high accuracy, high pneumothorax) and navigational bronchoscopy (lower pneumothorax, historically lower accuracy). The paper notes that no randomized trials have compared them and that estimates come from single-arm studies with bias. The hypothesis follows logically from the evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific premise by citing prior research on both modalities, acknowledging their limitations, and providing a logical rationale for the trial.

Evidence

paraphrase[Introduction, paragraph 1]

“Transthoracic biopsy is guided by intraprocedural three-dimensional CT images, providing an accurate diagnosis in up to 90% of cases, but requires passing a needle through the chest wall and pleura causing pneumothorax in up to 25% of cases.”

direct quote[Introduction, paragraph 2]

“No randomized trials have compared navigational bronchoscopy to transthoracic biopsy.”